CP-155 Prevalence and effectiveness of antiretroviral treatment combinations used in hiv patients not included in guidelines

BackgroundMost studies in HIV infected patients focus on the effectiveness of antiretroviral therapy (ART) combinations included in clinical guidelines. However, few studies have analysed combinations not listed in these guidelines.PurposeTo analyse the prevalence and effectiveness of ART combinatio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2017-03, Vol.24 (Suppl 1), p.A69-A70
Hauptverfasser: Gonzalez, L Ruiz, Nonay, A Alvarez, de Suso, M Torralba Gonzalez, Zapata, M Rodriguez, Hernandez, AM Horta, Lopez, A Lazaro
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A70
container_issue Suppl 1
container_start_page A69
container_title European journal of hospital pharmacy. Science and practice
container_volume 24
creator Gonzalez, L Ruiz
Nonay, A Alvarez
de Suso, M Torralba Gonzalez
Zapata, M Rodriguez
Hernandez, AM Horta
Lopez, A Lazaro
description BackgroundMost studies in HIV infected patients focus on the effectiveness of antiretroviral therapy (ART) combinations included in clinical guidelines. However, few studies have analysed combinations not listed in these guidelines.PurposeTo analyse the prevalence and effectiveness of ART combinations not included in HIV guidelines.Material and methodsA retrospective observational study was carried out between January 2014 and December 2015. All patients with ART followed for at least 1 year by the outpatient pharmacy were included. ART were classified in two groups:(1) all combinations listed in the Spanish National AIDS Plan Recommended Guidelines (GESIDA) for initial antiretroviral therapy 2014–2015; and combinations not listed in GESIDA Guidelines.To determine the effectiveness of the treatment, plasma viral load (VL) and CD4+ lymphocytes were reviewed. Two analyses according to different criteria were conducted:(1) criteria reflected in Spanish GESIDA guidelines: VL 300 cells/μL, on at least two consecutive occasions;(2) criteria reflected in the American DHHS guidelines: VL 300 cells/μL, on at least two consecutive occasions. Data were analysed with SPSS 20.0 software.Results245 patients were analysed. 68.6% (168) were men. The median age was 48.5 years (IIC: 43.5 to 53). Patients ART combinations included in guidelinesART combinationsnot included in guidelines Total (n (%)) 224 (91.4) 21 (8.6) VL 300 cells/μL (n (%)) 110 (49.1) 9 (42.9) OR=1.287 95% CI OR: 0.521–3.174 p=0.584 VL 300 cells/μL (n (%)) 174 (77.7) 14 (66.7) OR=1.740 95% CI OR: 0.666–4.545 p=0.253 ConclusionThis study shows that few patients receive ART combinations not included in clinical practice guidelines. The high power of current ART could explain the similar effectiveness between the listed and non-listed therapies in the guidelines.No conflict of interest
doi_str_mv 10.1136/ejhpharm-2017-000640.154
format Article
fullrecord <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2552765471</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2552765471</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1001-88c32f72da40a3c20ac75dfc170b979e03d2042cb655d626fbd53b49f94079b53</originalsourceid><addsrcrecordid>eNp9kUtLAzEUhQdRsGj_Q8D1aN5pllJ8gaALXYe8xqbMZGqSKbgRN_5Rf4kpVZeu7uWcw7lcvqYBCJ4jRPiFX682K52GFkMkWgghp9Vh9KCZYUhFKyWnh38748fNPOdgICNkISmRs-Z9-dgixr4-Ph-T3-reR-uBjg74rvO2hK2PPmcwdlUsIfmSxm1IugcleV0GHwuw42BC1CWMMYMpewdCBKuwBZuq1UAGcSxVs_3k9ubLFJzvQ20-bY463Wc__5knzfP11dPytr1_uLlbXt63BkGI2sXCEtwJ7DSFmlgMtRXMdRYJaKSQHhJXf8TWcMYcx7wzjhFDZScpFNIwctKc7Xs3aXydfC5qPU4p1pMKM4YFZ1Sg_1JoIQiXGEteU2SfMsNabVIYdHpTCKodEfVLRO2IqD0RVYmQb2oDgpk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1873692296</pqid></control><display><type>article</type><title>CP-155 Prevalence and effectiveness of antiretroviral treatment combinations used in hiv patients not included in guidelines</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Gonzalez, L Ruiz ; Nonay, A Alvarez ; de Suso, M Torralba Gonzalez ; Zapata, M Rodriguez ; Hernandez, AM Horta ; Lopez, A Lazaro</creator><creatorcontrib>Gonzalez, L Ruiz ; Nonay, A Alvarez ; de Suso, M Torralba Gonzalez ; Zapata, M Rodriguez ; Hernandez, AM Horta ; Lopez, A Lazaro</creatorcontrib><description>BackgroundMost studies in HIV infected patients focus on the effectiveness of antiretroviral therapy (ART) combinations included in clinical guidelines. However, few studies have analysed combinations not listed in these guidelines.PurposeTo analyse the prevalence and effectiveness of ART combinations not included in HIV guidelines.Material and methodsA retrospective observational study was carried out between January 2014 and December 2015. All patients with ART followed for at least 1 year by the outpatient pharmacy were included. ART were classified in two groups:(1) all combinations listed in the Spanish National AIDS Plan Recommended Guidelines (GESIDA) for initial antiretroviral therapy 2014–2015; and combinations not listed in GESIDA Guidelines.To determine the effectiveness of the treatment, plasma viral load (VL) and CD4+ lymphocytes were reviewed. Two analyses according to different criteria were conducted:(1) criteria reflected in Spanish GESIDA guidelines: VL &lt;50 copies/mL (undetectable) and CD4 repeatedly &gt;300 cells/μL, on at least two consecutive occasions;(2) criteria reflected in the American DHHS guidelines: VL &lt;200 copies/mL (to prevent errors by blip) and CD4 repeatedly &gt;300 cells/μL, on at least two consecutive occasions. Data were analysed with SPSS 20.0 software.Results245 patients were analysed. 68.6% (168) were men. The median age was 48.5 years (IIC: 43.5 to 53). Patients ART combinations included in guidelinesART combinationsnot included in guidelines Total (n (%)) 224 (91.4) 21 (8.6) VL &lt;50 copies/mL and CD4 &gt;300 cells/μL (n (%)) 110 (49.1) 9 (42.9) OR=1.287 95% CI OR: 0.521–3.174 p=0.584 VL &lt;200 copies/mL and CD4 &gt;300 cells/μL (n (%)) 174 (77.7) 14 (66.7) OR=1.740 95% CI OR: 0.666–4.545 p=0.253 ConclusionThis study shows that few patients receive ART combinations not included in clinical practice guidelines. The high power of current ART could explain the similar effectiveness between the listed and non-listed therapies in the guidelines.No conflict of interest</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2017-000640.154</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Antiretroviral drugs ; Drug therapy</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A69-A70</ispartof><rights>2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2017 (c) 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2017 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Gonzalez, L Ruiz</creatorcontrib><creatorcontrib>Nonay, A Alvarez</creatorcontrib><creatorcontrib>de Suso, M Torralba Gonzalez</creatorcontrib><creatorcontrib>Zapata, M Rodriguez</creatorcontrib><creatorcontrib>Hernandez, AM Horta</creatorcontrib><creatorcontrib>Lopez, A Lazaro</creatorcontrib><title>CP-155 Prevalence and effectiveness of antiretroviral treatment combinations used in hiv patients not included in guidelines</title><title>European journal of hospital pharmacy. Science and practice</title><description>BackgroundMost studies in HIV infected patients focus on the effectiveness of antiretroviral therapy (ART) combinations included in clinical guidelines. However, few studies have analysed combinations not listed in these guidelines.PurposeTo analyse the prevalence and effectiveness of ART combinations not included in HIV guidelines.Material and methodsA retrospective observational study was carried out between January 2014 and December 2015. All patients with ART followed for at least 1 year by the outpatient pharmacy were included. ART were classified in two groups:(1) all combinations listed in the Spanish National AIDS Plan Recommended Guidelines (GESIDA) for initial antiretroviral therapy 2014–2015; and combinations not listed in GESIDA Guidelines.To determine the effectiveness of the treatment, plasma viral load (VL) and CD4+ lymphocytes were reviewed. Two analyses according to different criteria were conducted:(1) criteria reflected in Spanish GESIDA guidelines: VL &lt;50 copies/mL (undetectable) and CD4 repeatedly &gt;300 cells/μL, on at least two consecutive occasions;(2) criteria reflected in the American DHHS guidelines: VL &lt;200 copies/mL (to prevent errors by blip) and CD4 repeatedly &gt;300 cells/μL, on at least two consecutive occasions. Data were analysed with SPSS 20.0 software.Results245 patients were analysed. 68.6% (168) were men. The median age was 48.5 years (IIC: 43.5 to 53). Patients ART combinations included in guidelinesART combinationsnot included in guidelines Total (n (%)) 224 (91.4) 21 (8.6) VL &lt;50 copies/mL and CD4 &gt;300 cells/μL (n (%)) 110 (49.1) 9 (42.9) OR=1.287 95% CI OR: 0.521–3.174 p=0.584 VL &lt;200 copies/mL and CD4 &gt;300 cells/μL (n (%)) 174 (77.7) 14 (66.7) OR=1.740 95% CI OR: 0.666–4.545 p=0.253 ConclusionThis study shows that few patients receive ART combinations not included in clinical practice guidelines. The high power of current ART could explain the similar effectiveness between the listed and non-listed therapies in the guidelines.No conflict of interest</description><subject>Antiretroviral drugs</subject><subject>Drug therapy</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kUtLAzEUhQdRsGj_Q8D1aN5pllJ8gaALXYe8xqbMZGqSKbgRN_5Rf4kpVZeu7uWcw7lcvqYBCJ4jRPiFX682K52GFkMkWgghp9Vh9KCZYUhFKyWnh38748fNPOdgICNkISmRs-Z9-dgixr4-Ph-T3-reR-uBjg74rvO2hK2PPmcwdlUsIfmSxm1IugcleV0GHwuw42BC1CWMMYMpewdCBKuwBZuq1UAGcSxVs_3k9ubLFJzvQ20-bY463Wc__5knzfP11dPytr1_uLlbXt63BkGI2sXCEtwJ7DSFmlgMtRXMdRYJaKSQHhJXf8TWcMYcx7wzjhFDZScpFNIwctKc7Xs3aXydfC5qPU4p1pMKM4YFZ1Sg_1JoIQiXGEteU2SfMsNabVIYdHpTCKodEfVLRO2IqD0RVYmQb2oDgpk</recordid><startdate>201703</startdate><enddate>201703</enddate><creator>Gonzalez, L Ruiz</creator><creator>Nonay, A Alvarez</creator><creator>de Suso, M Torralba Gonzalez</creator><creator>Zapata, M Rodriguez</creator><creator>Hernandez, AM Horta</creator><creator>Lopez, A Lazaro</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>201703</creationdate><title>CP-155 Prevalence and effectiveness of antiretroviral treatment combinations used in hiv patients not included in guidelines</title><author>Gonzalez, L Ruiz ; Nonay, A Alvarez ; de Suso, M Torralba Gonzalez ; Zapata, M Rodriguez ; Hernandez, AM Horta ; Lopez, A Lazaro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1001-88c32f72da40a3c20ac75dfc170b979e03d2042cb655d626fbd53b49f94079b53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antiretroviral drugs</topic><topic>Drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gonzalez, L Ruiz</creatorcontrib><creatorcontrib>Nonay, A Alvarez</creatorcontrib><creatorcontrib>de Suso, M Torralba Gonzalez</creatorcontrib><creatorcontrib>Zapata, M Rodriguez</creatorcontrib><creatorcontrib>Hernandez, AM Horta</creatorcontrib><creatorcontrib>Lopez, A Lazaro</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gonzalez, L Ruiz</au><au>Nonay, A Alvarez</au><au>de Suso, M Torralba Gonzalez</au><au>Zapata, M Rodriguez</au><au>Hernandez, AM Horta</au><au>Lopez, A Lazaro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CP-155 Prevalence and effectiveness of antiretroviral treatment combinations used in hiv patients not included in guidelines</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2017-03</date><risdate>2017</risdate><volume>24</volume><issue>Suppl 1</issue><spage>A69</spage><epage>A70</epage><pages>A69-A70</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>BackgroundMost studies in HIV infected patients focus on the effectiveness of antiretroviral therapy (ART) combinations included in clinical guidelines. However, few studies have analysed combinations not listed in these guidelines.PurposeTo analyse the prevalence and effectiveness of ART combinations not included in HIV guidelines.Material and methodsA retrospective observational study was carried out between January 2014 and December 2015. All patients with ART followed for at least 1 year by the outpatient pharmacy were included. ART were classified in two groups:(1) all combinations listed in the Spanish National AIDS Plan Recommended Guidelines (GESIDA) for initial antiretroviral therapy 2014–2015; and combinations not listed in GESIDA Guidelines.To determine the effectiveness of the treatment, plasma viral load (VL) and CD4+ lymphocytes were reviewed. Two analyses according to different criteria were conducted:(1) criteria reflected in Spanish GESIDA guidelines: VL &lt;50 copies/mL (undetectable) and CD4 repeatedly &gt;300 cells/μL, on at least two consecutive occasions;(2) criteria reflected in the American DHHS guidelines: VL &lt;200 copies/mL (to prevent errors by blip) and CD4 repeatedly &gt;300 cells/μL, on at least two consecutive occasions. Data were analysed with SPSS 20.0 software.Results245 patients were analysed. 68.6% (168) were men. The median age was 48.5 years (IIC: 43.5 to 53). Patients ART combinations included in guidelinesART combinationsnot included in guidelines Total (n (%)) 224 (91.4) 21 (8.6) VL &lt;50 copies/mL and CD4 &gt;300 cells/μL (n (%)) 110 (49.1) 9 (42.9) OR=1.287 95% CI OR: 0.521–3.174 p=0.584 VL &lt;200 copies/mL and CD4 &gt;300 cells/μL (n (%)) 174 (77.7) 14 (66.7) OR=1.740 95% CI OR: 0.666–4.545 p=0.253 ConclusionThis study shows that few patients receive ART combinations not included in clinical practice guidelines. The high power of current ART could explain the similar effectiveness between the listed and non-listed therapies in the guidelines.No conflict of interest</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2017-000640.154</doi></addata></record>
fulltext fulltext
identifier ISSN: 2047-9956
ispartof European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A69-A70
issn 2047-9956
2047-9964
language eng
recordid cdi_proquest_journals_2552765471
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Antiretroviral drugs
Drug therapy
title CP-155 Prevalence and effectiveness of antiretroviral treatment combinations used in hiv patients not included in guidelines
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T22%3A56%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CP-155%E2%80%85Prevalence%20and%20effectiveness%20of%20antiretroviral%20treatment%20combinations%20used%20in%20hiv%20patients%20not%20included%20in%20guidelines&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Gonzalez,%20L%20Ruiz&rft.date=2017-03&rft.volume=24&rft.issue=Suppl%201&rft.spage=A69&rft.epage=A70&rft.pages=A69-A70&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2017-000640.154&rft_dat=%3Cproquest_bmj_p%3E2552765471%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1873692296&rft_id=info:pmid/&rfr_iscdi=true